

NCCN Kidney Cancer Guidelines V.1.2012 – Update Meeting – 08/15/11

Guideline Page and Request	Panel Discussion	References	Vote		
			YES	NO	ABSTAIN
<p>KID-3 and KID-4 Internal request: Institutional Review comment for the inclusion of denosumab for bony metastases.</p> <p>External request: Submission from Amgen, Inc for denosumab be added as first-line therapy for the prevention of skeletal-related events in patients with bone metastases from kidney cancer.</p>	Based on the data in the noted reference, the panel consensus was to add the drug class RANK ligand inhibitors to footnote h for the treatment of bony metastases.	Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-1132.	14	0	0

NCCN Testicular Cancer V.1.2012 – Update Meeting – August 15, 2011

Guideline Page and Request	Panel Discussion	References	Vote		
			YES	NO	ABSTAIN
<p>TEST-D Internal request: Panel discussion to consider additional combination chemotherapy regimens for palliative therapy: gemcitabine/paclitaxel and gemcitabine/paclitaxel/oxaliplatin</p>	<p>The chemotherapy options listed for palliative therapy for patients with testicular cancer were reviewed. Based on the noted references, the Panel consensus was to add the combinations of gemcitabine/paclitaxel and gemcitabine/paclitaxel/oxaliplatin as therapeutic options for these patients.</p>	<p>Paclitaxel/gemcitabine</p> <ol style="list-style-type: none"> 1. Einhorn LH, Brames MJ, Juliar B, Williams SD. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J Clin Oncol 2007;25:513-516. 2. Mulherin B, Brames M, Einhorn L. Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplants [abstract]. J Clin Oncol 2011;29:Abstract 4562. <p>Gemcitabine/oxaliplatin/paclitaxel</p> <ol style="list-style-type: none"> 1. Bokemeyer C, Oechsle K, Honecker F, Mayer F, Hartmann JT, Waller CF, Böhlke I, Kollmannsberger C; German Testicular Cancer Study Group. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: A study of the German Testicular Cancer Study Group. Ann Oncol 2008;19:448-453. 	14	0	0